Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2014 04:13 ET | Source: Andromeda Biotech Ltd.

Andromeda Acquires DiaPep277 Rights From Teva

YAVNE, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that it entered into an agreement with Teva Pharmaceutical Industries Ltd. for the acquisition of Teva's rights for...
January 12, 2014 09:12 ET | Source: Andromeda Biotech Ltd.

Andromeda Announces the Acceptance of Two Manuscripts for Publication Describing Its Phase 3 DIA-AID 1 Study

YAVNE, Israel, Jan. 12, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that two peer-reviewed articles were accepted for publication in Diabetes Care. The publications, which discuss...
December 18, 2013 08:32 ET | Source: Andromeda Biotech Ltd.

Andromeda Announces First Patient Dosed in Extension Study to Its Phase 3 Clinical Trial DIA-AID 2 in Patients With Type 1 Diabetes

YAVNE, Israel, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. today announces that the first patient was dosed with DiaPep277® for the treatment of type 1 diabetes in its Extension...
June 05, 2013 07:19 ET | Source: Andromeda Biotech Ltd.

Andromeda Announces the Results of an Extension to Its Phase III Study

YAVNE, Israel, June 5, 2013 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces the results from an Extension Study to its Phase III Clinical trial in type 1 diabetes patients treated with...
September 12, 2012 03:34 ET | Source: Andromeda Biotech Ltd.

Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Confirmatory Trial for Its Lead Drug, "DiaPep277" for Type 1 Diabetes

YAVNE, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. (www.andromedabio.com) announced today that it has completed patient recruitment in its' DIA-AID 2, a confirmatory Phase III...
May 28, 2012 06:45 ET | Source: Andromeda Biotech Ltd.

Andromeda Announces FDA Orphan Drug Designation for DiaPep277 for the Treatment of Type 1 Diabetes With Residual Beta Cell Function

YAVNE, Israel, May 28, 2012 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. today announces that the US Food and Drug Administration (FDA) granted Orphan Drug designation for DiaPep277® for the...
May 09, 2012 12:21 ET | Source: Andromeda Biotech Ltd.

Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study

YAVNE, Israel, May 9, 2012 (GLOBE NEWSWIRE) -- Clal Biotechnology Industries Ltd. today announces that further analyses of initial data support the achieved primary endpoint of Andromeda Biotech's...
November 22, 2011 10:38 ET | Source: Andromeda Biotech Ltd.

Andromeda Announces Phase III Clinical Study With DiaPep277(R), a Novel Immunotherapeutic Agent for Type 1 Diabetes, Met Primary Endpoint

DiaPep277® Demonstrated a Significant Preservation of C-peptide Levels, a Marker for Assessing Insulin Secretion by Pancreatic Cells Higher Proportion of Patients Maintained Adequate Diabetic...
June 17, 2010 07:41 ET | Source: Andromeda Biotech Ltd.

Teva Exercises Option to Invest in Andromeda Biotech

YAVNE, Israel, June 17, 2010 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd....